Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ:COLL) and maintained a $40 price target.
February 02, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Collegium Pharmaceutical with a $40 price target.
The reiteration of a Buy rating and maintenance of a $40 price target by a reputable analyst suggests a positive outlook for Collegium Pharmaceutical. This endorsement could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100